CoChat

Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis

Werfel, Thomas, Layton, Gary, Yeadon, Michael, Whitlock, Lyndsey, Osterloh, Ian, Jimenez, Pablo, Liu, Wai, Lynch, Victoria, Asher, Aliya, Tsianakas, Athanasios, Purkins, Lynn · 2019 · Journal of Allergy and Clinical Immunology
Cited by 139

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Background: H4 receptor antagonists are potential novel treatments for inflammatory skin diseases, including atopic dermatitis (AD). Objective: We sought to study the efficacy and safety of ZPL‐3893787 (a selective H4 receptor antagonist) in patients with moderate‐to‐severe AD. Methods: A randomized, double‐blind, placebo‐controlled, parallel‐group study was conducted to evaluate ZPL‐3893787 (30 mg) once‐daily oral therapy in adults with moderate‐to‐severe AD. Patients were randomized (2:1) to ZPL‐3893787 (n = 65) or placebo (n = 33) for 8 weeks. Patients had a history of AD for more than 12 months, Eczema Area and Severity Index (EASI) scores of 12 or greater and 48 or less, Investigator's Global Assessment (IGA) scores of 3 or greater, pruritus scores of 5 or greater (0‐ to 10‐point scale), and AD on 10% or greater of body surface area. Efficacy parameters included EASI, IGA, SCORAD, and pruritus assessment. Results: Treatment with oral ZPL‐3893787 showed a 50% reduction in EASI score compared with 27% for placebo. The placebo‐adjusted reduction in EASI score at week 8 was 5.1 (1‐sided P = .01). Clear or almost‐clear IGA scores were 18.5% with ZPL‐3893787 versus 9.1% with placebo. SCORAD scores exhibited 41% reduction with ZPL‐3893787 versus 26% with placebo (placebo‐adjusted reduction of 10.0, P = .004). There was a 3‐point reduction (scale, 1‐10) in pruritus with ZPL‐3893787, but there was a similar reduction with placebo, resulting in a nonsignificant difference (P = .249). Patient‐reported pruritus subscores obtained from SCORAD were reduced with ZPL‐3893787 compared with placebo at week 8 (nonsignificant). ZPL‐3893787 was well tolerated. Conclusion: For the first time, these results showed that ZPL‐3893787 improved inflammatory skin lesions in patients with AD, confirming H4 receptor antagonism as a novel therapeutic option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2018.07.047

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 139

Metadata

Authors
Werfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., Liu, W., Lynch, V., Asher, A., Tsianakas, A., & Purkins, L.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2019-05
Volume
143
Issue
5
Pages
1830-1837.e4
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2900407403
Cited by
139
References
3
FWCI
18.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.